Suppr超能文献

早期乳腺癌围手术期化疗后局部控制和无病生存率的改善。一项欧洲癌症研究与治疗组织乳腺癌协作组的研究。

Improved local control and disease-free survival after perioperative chemotherapy for early-stage breast cancer. A European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group Study.

作者信息

Clahsen P C, van de Velde C J, Julien J P, Floiras J L, Delozier T, Mignolet F Y, Sahmoud T M

机构信息

University Hospital Leiden, Department of Surgery, the Netherlands.

出版信息

J Clin Oncol. 1996 Mar;14(3):745-53. doi: 10.1200/JCO.1996.14.3.745.

Abstract

PURPOSE

To investigate whether a short intensive course of perioperative polychemotherapy can change the course of early breast cancer.

PATIENTS AND METHODS

A total of 2,795 women with early breast cancer, stage I to IIIA, were randomized onto a trial (European Organization for Research and Treatment of Cancer [EORTC] 10854) to compare surgery followed by one course of perioperative chemotherapy versus surgery alone. Patients assigned to the chemotherapy arm received one course of fluorouracil 600 mg/m2, doxorubicin 50 mg/m2, and cyclophosphamide 600 mg/m2 (FAC) intravenously, within 24 hours after surgery. In both randomized treatment arms, a recommendation was made for premenopausal women with positive axillary nodes to receive prolonged courses of cyclophosphamide, methotrexate, and fluorouracil (CMF), according to the standard treatment for this subgroup.

RESULTS

At a median follow-up time of 41 months, local control was significantly better in the perioperative treatment arm as compared with the observation arm (hazards ratio, 0.60; 95% confidence interval, 0.44 to 0.83; P < .01). Disease-free survival was significantly prolonged in the chemotherapy arm (hazards ratio, 0.84; 95% confidence interval, 0.70 to 0.99; P = .04). Premenopausal node-negative patients especially showed an advantage for the perioperative chemotherapy arm. No advantage for perioperative chemotherapy was observed in premenopausal node-positive women who also had received prolonged chemotherapy.

CONCLUSION

We conclude that one course of perioperative FAC is able to improve local control and can prolong disease-free survival in women with early breast cancer. However, our results also suggest that a perioperative timing cannot improve the results of standard prolonged chemotherapy in premenopausal women with positive axillary nodes.

摘要

目的

研究围手术期短期强化多药化疗能否改变早期乳腺癌的病程。

患者与方法

共有2795例Ⅰ至ⅢA期早期乳腺癌女性患者被随机纳入一项试验(欧洲癌症研究与治疗组织[EORTC]10854),以比较手术加一个疗程围手术期化疗与单纯手术的效果。分配到化疗组的患者在术后24小时内静脉接受一个疗程的氟尿嘧啶600mg/m²、多柔比星50mg/m²和环磷酰胺600mg/m²(FAC)。在两个随机治疗组中,均建议绝经前腋窝淋巴结阳性的女性患者按照该亚组的标准治疗方案接受延长疗程的环磷酰胺、甲氨蝶呤和氟尿嘧啶(CMF)治疗。

结果

在中位随访时间41个月时,围手术期治疗组的局部控制情况明显优于观察组(风险比,0.60;95%置信区间,0.44至0.83;P<.01)。化疗组的无病生存期显著延长(风险比,0.84;95%置信区间,0.70至0.99;P = .04)。绝经前淋巴结阴性的患者在围手术期化疗组中尤其显示出优势。在也接受了延长化疗的绝经前淋巴结阳性女性中未观察到围手术期化疗的优势。

结论

我们得出结论,一个疗程的围手术期FAC能够改善局部控制,并可延长早期乳腺癌女性患者的无病生存期。然而,我们的结果也表明,围手术期化疗时机并不能改善绝经前腋窝淋巴结阳性女性患者标准延长化疗的效果。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验